NCT05792267 Clinical Research on a Novel Deep-learning Based System in Pancreatic Endoscopic Ultrasound Scanning
| NCT ID | NCT05792267 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Third Xiangya Hospital of Central South University |
| Condition | Pancreatic Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2021-01-01 |
| Primary Completion | 2024-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2021-01-01 with a primary completion date of 2024-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to develop and verify the auxiliary role of the artificial intelligence system in pancreatic ultrasound endoscopic scanning.The main questions it aims to answer are as follows: 1.The comparison of the image recognition accuracy between the artificial intelligence system and the ultrasound endoscopist; 2. Whether the artificial intelligence system can improve the efficiency of the pancreatic scanning for the ultrasound endoscopist. Participants will undergo pancreatic EUS with or without the assistance of the artificial intelligence system.
Eligibility Criteria
Inclusion Criteria: * 1\. Age ≥18 years old, \<80 years old 2.Patients who need endoscopic ultrasonography of pancreas; 3. Agree to participate in this study and sign the informed consent form. Exclusion Criteria: * Subjects who meet any of the following criteria cannot be selected for this trial: First. The patient's physical condition does not meet the requirements of conventional endoscopic ultrasonography: 1. Poor physical condition, including hemoglobin ≤8.0g/dl, severe cardiopulmonary insufficiency, etc. 2. Anesthesia assessment failed 3. Pregnancy or breastfeeding 4. In the acute stage of chemical and corrosive injury, it is very easy to cause perforation 5. Recent acute coronary syndrome or clinically unstable ischemic heart attack 6. Heart disease patients with right-to-left shunt, patients with severe pulmonary hypertension (pulmonary artery pressure\> 90mmHg),patients with uncontrolled systemic hypertension and patients with adult respiratory distress syndrome. Second. Disagree to participate in this study. Third. There are other problems that do not meet the requirements of this research or that affect the results of the research: 1. Pancreatic disease has undergone surgery or radiotherapy and chemotherapy beforehand; 2. Mental illness, drug addiction, inability to express themselves or other diseases that may affect follow-up.
Contact & Investigator
Xiaoyan Wang, Doctor
PRINCIPAL INVESTIGATOR
The Third Xiangya Hospital of Central South University
Frequently Asked Questions
Who can join the NCT05792267 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Pancreatic Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05792267 currently recruiting?
Yes, NCT05792267 is actively recruiting participants. Contact the research team at wxy20011@163.com for enrollment information.
Where is the NCT05792267 trial being conducted?
This trial is being conducted at Changsha, China.
Who is sponsoring the NCT05792267 clinical trial?
NCT05792267 is sponsored by The Third Xiangya Hospital of Central South University. The principal investigator is Xiaoyan Wang, Doctor at The Third Xiangya Hospital of Central South University. The trial plans to enroll 200 participants.